Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Short-term Investments (2023 - 2025)

Historic Short-term Investments for Genmab A (GMAB) over the last 3 years, with Q3 2025 value amounting to $140.0 million.

  • Genmab A's Short-term Investments rose 22558.14% to $140.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.0 million, marking a year-over-year increase of 22558.14%. This contributed to the annual value of $11.0 million for FY2024, which is 9450.0% down from last year.
  • Per Genmab A's latest filing, its Short-term Investments stood at $140.0 million for Q3 2025, which was up 22558.14% from $122.0 million recorded in Q2 2025.
  • In the past 5 years, Genmab A's Short-term Investments ranged from a high of $200.0 million in Q4 2023 and a low of $2.0 million during Q2 2024
  • Moreover, its 3-year median value for Short-term Investments was $101.0 million (2025), whereas its average is $91.0 million.
  • Per our database at Business Quant, Genmab A's Short-term Investments tumbled by 9450.0% in 2024 and then soared by 600000.0% in 2025.
  • Quarter analysis of 3 years shows Genmab A's Short-term Investments stood at $200.0 million in 2023, then crashed by 94.5% to $11.0 million in 2024, then surged by 1172.73% to $140.0 million in 2025.
  • Its Short-term Investments was $140.0 million in Q3 2025, compared to $122.0 million in Q2 2025 and $80.0 million in Q1 2025.